# Research Pulse — 2026-10-04 _Generated 2026-10-04 07:33 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 10월 4일 (일요일) · Accelerating(가속) Day** 10/04(가속) → 10/03(수렴) → 10/02(정착) → 10/01(임상 전환) → 9/30(번역) → 9/29(안착) → 9/28(제도화) → 9/27(성숙). Converging(10/03)된 기술들이 **실질적 임상·규제 성과로 가속화(Accelerating)하는 날** — Lushington et al.로 PE first-in-human functional restoration + encouraging safety profile 확인(Molecular Therapy 2026), Jong et al.로 PE7까지 7단계 evolution + in vivo delivery breakthrough 동시 확인(BMB Reports 2026), Yu et al.로 PE efficiency enhancement + capacity expansion 체계적 review(Advanced Science 2026), Singh et al.로 AlphaFold drug discovery 적용 한계 — Protein-Ligand data 필요성 + current models drug discovery tasks 한계 체계적 분석(Current Opinion Structural Biology 2026), Yoo et al.로 AI-designed TNIK inhibitor Phase IIa efficacy 확인 + adaptive trial design + federated model validation(BJC Reports 2026), Lin et al.로 2026 pharma AI deal flurry — Isomorphic Labs·Exscientia·Recursion Pharologi 대규모 투자 accelerated(LIN GEN Biotechnology 2026), Cervilla et al.로 spatial transcriptomics 5개 플랫폼 head-to-head FFPE benchmark — Visium HD·Xenium·CosMx 기술적 convergence 체계적 비교(Genome Biology 2026), Sheikh et al.로 Kresladi FDA 2026년 3월 승인 — LAD-I gene therapy 구체적 approval 현실 + ITGB2 hematopoietic stem cell editing 승인 현실(Annals of Medicine 2026)이 동시에 진행된다. Accelerating은 Converging(10/03)의 다음 단계다. 오늘 6개 전선은 수렴된 기술들이 **실질적 임상·규제 성과로 가속화(Accelerating)하는 날**이다. *출처: [Lushington PE First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Jong PE Evolution BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/), [Yu PE Efficiency Advanced Science 2026](https://consensus.app/papers/details/475fc3cbbe805f5e915626f08d2da039/), [Singh AlphaFold Drug Discovery Limitation Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Yoo TNIK Phase IIa BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Lin Pharma AI 2026 Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Cervilla 5-Platform Benchmark Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/), [Sheikh Kresladi LAD-I Annals of Medicine 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/)* *#AcceleratingDay #Lushington #MolecularTherapy #PrimeEditing #FirstInHuman #FunctionalRestoration #Jong #BMBReports #PE7 #Evolution #Yu #AdvancedScience #PEEfficiency #Singh #AlphaFold #DrugDiscovery #Limitation #ProteinLigand #Yoo #TNIK #PhaseIIa #BJCReports #AdaptiveTrial #FederatedModel #Lin #GENBiotechnology #PharmaAI #2026Deals #IsomorphicLabs #Exscientia #Recursion #Cervilla #GenomeBiology #SpatialTranscriptomics #Benchmark #5Platforms #Sheikh #Kresladi #LADI #ITGB2 #March2026 #AnnalsOfMedicine #Accelerating #ClinicalAcceleration #RegulatoryApproval #BiomedicalAI #DailyReport* --- ### Post 2: CRISPR & Gene Editing — PE First-in-Human + PE7 Evolution + Efficiency Enhancement: Accelerating 🪄 **[CRISPR/Gene Editing] Lushington et al.로 PE first-in-human functional restoration + promising safety profile 확인(Molecular Therapy 2026) + Jong et al.로 PE1→PE7까지 7단계 evolution + in vivo delivery breakthrough + methodological expansion 체계적 review(BMB Reports 2026) + Yu et al.로 PE efficiency enhancement + capacity expansion + all types of point mutations 가능성 체계적 review(Advanced Science 2026): PE Accelerating(가속) 동시 확인** CRISPR prime editing의 **first-in-human 성적 + 기술 evolution 가속화(Accelerating)**가 출처에서 동시에 확인된다[1][2][3]. **PE First-in-Human: Functional Restoration + Promising Safety Profile[1]** Caleb Lushington et al.(Molecular Therapy 2026)의 review는 PE의 first-in-human study 결과를 분석한다[1]. PE가 double-strand breaks 없이 precise custom edits를 설치하며, Cas9 nickase + reverse transcriptase fusion + pegRNA로 작동한다. PE1에서 PE7까지 Cas variant selection, RT engineering, pegRNA improvements로 efficiency가 크게 향상되었다. **First-in-human study**: functional restoration 확인 + promising safety profile 지금까지 보고. In vivo delivery technologies(nanoparticles, split viral systems)로 preclinical disease models에서 rapid advances 달성. **남은 도전과제**: efficiency, delivery, safety의 브로드 clinical impact를 위해 해결 필요. 핵심: PE first-in-human functional restoration + encouraging safety profile 확인 — 임상 가속화. **PE1→PE7 Evolution: 7단계 Methodological Expansion[2]** Uijin Jong et al.(BMB Reports 2026)의 review는 PE의 technological evolution을 종합한다[2]. PE1(2019년 최초보고) → PE7까지 methodology evolution을 체계적으로 분석한다. **Edits의 범위**: base substitutions, insertions, deletions, all types of point mutations. **In vivo delivery**: nanoparticles + split viral systems breakthrough로 치료 적용 확대. ** Efficiency 향상**: Cas variant selection + RT engineering + pegRNA improvements. **Editable target range expansion**: large genomic regions correction 가능. 핵심: PE7까지 7단계 evolution으로 in vivo delivery breakthrough 달성 — 기술 가속화. **PE Efficiency Enhancement: Capacity Expansion[3]** Jihyeon Yu et al.(Advanced Science 2026)의 review는 PE efficiency enhancement 전략을 분석한다[3]. CRISPR-Cas9이 2012년 이후 genome editing을 revolution했으며, base editors로 point mutations 도입이 가능해졌고, PE로 insertions, deletions, all types of point mutations가 가능해졌다. **PE의 잠재적 한계**: low editing efficiency + limited capacity for large-scale manipulation. **현재 향상 노력**: PE efficiency 향상 + capabilities 확장 위한 지속적 연구 진행. 핵심: PE efficiency enhancement + capacity expansion 지속적 진행 — 기술 가속화. **10월 3일 Converging(Şahin global trajectory + Freedman monitoring toolkit) vs 오늘의 차별점**: 10/03이 **Şahin Molecular Therapy**으로 ClinicalTrials.gov/EUCTR注册的 2026년 9월 기준update 글로벌 임상 시험 trajectory를, **Freedman Nature Reviews Genetics**으로 nucleotides→organism whole-scale regulatory-grade monitoring toolkit을 제시했다면, 오늘은 **Lushington Molecular Therapy**으로 **PE first-in-human functional restoration + safety profile**이라는 구체적 임상 성적(가속화)을, **Jong BMB Reports**으로 **PE1→PE7 7단계 evolution + in vivo delivery breakthrough**를(기술 evolution 가속화), **Yu Advanced Science**으로 **PE efficiency enhancement + capacity expansion**을(기술 가속화) 동시에 제시한다. Converging(10/03) → PE 임상 성과 + 기술 evolution 가속화 Accelerating(10/04). 실무 함의: 유전자 치료 개발팀에서 Lushington et al.의 first-in-human 결과를 참조하여 PE 임상 strategy를 수립해야 한다. *출처: [Lushington PE First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Jong PE Evolution BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/), [Yu PE Efficiency Advanced Science 2026](https://consensus.app/papers/details/475fc3cbbe805f5e915626f08d2da039/)* *#CRISPR #GeneEditing #PrimeEditing #Lushington #MolecularTherapy #FirstInHuman #FunctionalRestoration #SafetyProfile #Jong #BMBReports #PE7 #Evolution #InVivo #Delivery #Nanoparticles #Yu #AdvancedScience #PEEfficiency #CapacityExpansion #PointMutations #AcceleratingDay #ClinicalAcceleration #TechnologyEvolution #DeliveryBreakthrough #RTEngineering #pegRNA #BiomedicalAI #DailyReport* --- ### Post 3: AI 신약 — AI-Designed TNIK Phase IIa + Pharma AI 2026 Deal Flurry: Accelerating 💊 **[AI 신약] Yoo et al.로 AI-designed TNIK inhibitor Phase IIa efficacy validation + adaptive data-informed drug discovery + federated model validation + precision oncology 적용(BJC Reports 2026) + Lin et al.로 2026 pharma AI deal flurry — Isomorphic Labs·Exscientia·Recursion Pharologi 대규모 투자 accelerated(GEN Biotechnology 2026) + Singh et al.로 AlphaFold drug discovery 적용 한계 — Protein-Ligand data 필요성 + current models limitations 체계적 분석(Current Opinion Structural Biology 2026): AI Drug Discovery Accelerating(가속) 동시 확인** AI-Driven Drug Discovery의 **Phase IIa clinical milestone + pharma investment accelerated + AlphaFold limitation 체계적 인식(Accelerating)**이 출처에서 동시에 확인된다[4][5][6]. **AI-Designed TNIK Inhibitor Phase IIa: Clinical Milestone[4]** Wonbeak Yoo et al.(BJC Reports 2026)의 perspective는 AI-designed TNIK inhibitor의 Phase IIa efficacy를 분석한다[4]. AI로 설계된 TNIK inhibitor가 idiopathic pulmonary fibrosis(IPF) 환자에서 Phase IIa trial에서 efficacy를 확인했다. Safety, tolerability, pharmacodynamic target engagement가 확인되었으며, functional decline 감소 경향이 나타났다. AI-derived molecules가 human testing 진입 가능성을 입증했으나, broader validation, mechanistic understanding, regulatory alignment가 필요하다. **Adaptive data-informed drug discovery + federated model validation** 전략을 제시하며, precision oncology 적용 가능성을 논의한다. 핵심: AI-designed TNIK Phase IIa efficacy validation — AI drug discovery clinical milestone 가속화. **2026 Pharma AI Deal Flurry: Investment Accelerated[5]** Fay Lin(GEN Biotechnology 2026)의 기사는 2026년 pharma AI partnership 투자 급증세를 분석한다[5]. **Isomorphic Labs**(Google DeepMind 산하 구조biology AI company)가 big pharma와 다수 partnership을 맺었으며, **Exscientia**(AI-first drug discovery company)가 지속적 투자 유치를 받았고, **Recursion Pharologi**(automated biology platform)에도 pharma AI 투자가 확대되었다. 2026년 pharma AI platform에 대규모 투자가 급증하고 있으며, 독립적 AI-first company에 대한 pharma 투자도 지속 확대되고 있다. 핵심: 2026 pharma AI deal flurry — investment accelerated. **AlphaFold Drug Discovery Limitation: Protein-Ligand Data Gap[6]** Sukrit Singh et al.(Current Opinion in Structural Biology 2026)의 review는 AlphaFold의 drug discovery 적용 한계를 체계적으로 분석한다[6]. Structure-based drug design(SBDD)이 단백질 구조 정보를 소분자 치료제 설계에 활용하나, AlphaFold같은 PSPM의 limitations을 blinded challenges로 평가하고 real-world drug design tasks를 반영한 dataset 확장이 필수적이다. **현재 tasks**: PSPM이 잘 수행하는 tasks와 challenging/unexplored tasks를 계층적 프레임워크로 분석한다. **Frontier model 개발을 위한 dataset 생성의 중요성**: systematic dataset generation 필요. Experimental + physics-based datasets 생성 노력이 highlighting된다. 핵심: AlphaFold drug discovery limitation 체계적 분석 — Protein-Ligand data 필요성 인식. **10월 3일 Converging(Yoo TNIK Phase IIa + Mao Phase I/II + Cai preclinical) vs 오늘의 차별점**: 10/03이 **Yoo BJC Reports**으로 TNIK Phase IIa efficacy를, **Mao Frontiers Pharmacology**으로 Phase IIa + Phase I 동시 현실을, **Cai Pharmaceuticals**으로 preclinical pipeline 종합을 제시했다면, 오늘은 **Yoo 재확인**으로 **adaptive trial design + federated model validation이라는 구체적 임상 전략**을(가속화), **Lin GEN Biotechnology**으로 **2026 pharma AI deal flurry investment accelerated**를(투자 가속화), **Singh Current Opinion Structural Biology**으로 **AlphaFold drug discovery limitation 체계적 분석**을(한계 인식 가속화) 동시에 제시한다. Converging(10/03) → clinical milestone + investment + limitation 인식 가속화 Accelerating(10/04). 실무 함의: AI drug discovery 협업팀에서 Lin et al.의 2026 pharma AI deal 동향을 분석하여 partnership strategy를 수립해야 한다. *출처: [Yoo TNIK Phase IIa BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Lin Pharma AI 2026 Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Singh AlphaFold Drug Discovery Limitation Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)* *#AI #DrugDiscovery #Yoo #TNIK #PhaseIIa #BJCReports #AdaptiveTrial #FederatedModel #PrecisionOncology #Lin #GENBiotechnology #PharmaAI #2026Deals #IsomorphicLabs #Exscientia #Recursion #InvestmentFlurry #Singh #AlphaFold #CurrentOpinion #StructuralBiology #DrugDiscovery #Limitation #ProteinLigand #DataGap #FrontierModel #AcceleratingDay #ClinicalMilestone #InvestmentAccelerated #BiomedicalAI #DailyReport* --- ### Post 4: 단백질 AI — AlphaFold Drug Discovery Limitation 체계적 분석: Accelerating 🔬 **[단백질 AI] Singh et al.로 AlphaFold drug discovery 적용 한계 체계적 분석 — Protein-Ligand data 필요성 + hierarchical framework로 tasks 분류 + frontier model 개발 dataset 필요성(Current Opinion Structural Biology 2026) + Chakraborty et al.로 AF1→AF2→AF3 architectural evolution + SBDD 가속화 + protein dynamics挑战(Nature Biotechnology 2026) + Zhang et al.로 AlphaFold peptide structure prediction — ipTM score + molecular dynamics complementary approach(Biotechnology Advances 2026): 단백질 AI Accelerating(가속) 동시 확인** 단백질 AI의 **drug discovery 적용 한계 체계적 인식 + architecture evolution 가속화(Accelerating)**가 출처에서 동시에 확인된다[6][7][8]. **AlphaFold Drug Discovery Limitation: Protein-Ligand Data Gap[6]** Sukrit Singh et al.(Current Opinion in Structural Biology 2026)의 review는 AlphaFold의 drug discovery 적용 한계를 체계적으로 분석한다[6]. **Structure-based drug design(SBDD)**: protein 구조 정보를 소분자 치료제 설계에 활용. **PSPM의 한계**: blinded challenges로 평가 필요 + real-world drug design tasks를 반영한 dataset 확장 필수. **hierarchical framework**: current models가 잘 수행하는 tasks와 challenging/unexplored tasks를 계층적으로 분류. **Frontier model 개발을 위한 dataset 필요성**: experimental + physics-based datasets 생성 노력 highlighting. 핵심: AlphaFold drug discovery limitation 체계적 분석 — Protein-Ligand data gap 인식 가속화. **AlphaFold3 Evolution: AF1→AF2→AF3 Architectural Evolution[7]** Chakraborty, Bhattacharya & Lee(Frontiers in AI 2026)의 review는 AlphaFold 1→2→3의 architectural evolution과 translational research impact를 종합한다[7]. AF1은 DNN, AF2는 Evoformer, AF3는 Pairformer 아키텍처를 사용하며, 2024 Nobel Prize로 protein structure prediction 분야가 인정받았다. Structure-based drug discovery(SBDD)가 가속화되었으나 **protein dynamics와 multiple conformational states 예측의 도전과제**가 남아있다. 핵심: AF1→AF2→AF3 evolution + SBDD 가속화 — architecture evolution 가속화. **AlphaFold Peptide Structure: ipTM Score + Molecular Dynamics Complementary[8]** Buke Zhang et al.(Biotechnology Advances 2026)의 review는 AlphaFold series의 peptide structure prediction 적용과 한계를 분석한다[8]. AlphaFold2/3가 invariant point attention과 ipTM score로 monomeric peptide structures와 multi-chain complexes 예측 정확도를 달성했으나, **bioactive peptides가 binding 시 low-probability 상태를 취하는 경우 static predictions가 놓칠 수 있다**. Molecular dynamics simulations, free energy calculations, ensemble sampling과의 통합이 보완 전략으로 제시된다. 핵심: AlphaFold peptide 한계 + molecular dynamics 보완 전략 — 적용 가속화. **10월 3일 Converging(Lin oligomeric 4,700+ + Sarti Arity-Q) vs 오늘의 차별점**: 10/03이 **Lin Protein Science**으로 AlphaFold oligomeric state prediction 4,700+ proteins 대규모 검증을, **Sarti Bioinformatics Advances**으로 Arity-Q quality scoring을 제시했다면, 오늘은 **Singh Current Opinion Structural Biology**으로 **AlphaFold drug discovery limitation의 hierarchical framework 체계적 분석**이라는 새로운 관점(한계 인식 가속화)을, **Chakraborty Frontiers AI**으로 **AF1→AF2→AF3 evolution + SBDD 가속화**를(architecture evolution 가속화), **Zhang Biotechnology Advances**으로 **peptide prediction 한계 + MD 보완 전략**을(적용 가속화) 동시에 제시한다. Converging(10/03) → limitation 인식 + evolution + application 가속화 Accelerating(10/04). 실무 함의: 단백질 AI 팀에서 Singh et al.의 hierarchical framework를 참조하여 AlphaFold 적용 영역 선별 전략을 수립해야 한다. *출처: [Singh AlphaFold Drug Discovery Limitation Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Chakraborty AlphaFold3 Evolution Frontiers AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [Zhang AlphaFold Peptide Biotechnology Advances 2026](https://consensus.app/papers/details/948caefacacc54fcb7706db4d8660a93/)* *#ProteinAI #AlphaFold #Singh #CurrentOpinion #StructuralBiology #DrugDiscovery #Limitation #ProteinLigand #DataGap #HierarchicalFramework #FrontierModel #Chakraborty #AlphaFold3 #Evolution #Architectural #NobelPrize #SBDD #Zhang #BiotechnologyAdvances #PeptideStructure #ipTM #MolecularDynamics #FreeEnergy #EnsembleSampling #AcceleratingDay #LimitationRecognition #Evolution #Application #BiomedicalAI #DailyReport* --- ### Post 5: Single-Cell Multi-Omics Foundation Model — Real-World Benchmark + Parameter-Free > FM: Accelerating 🬬 **[Single-Cell Multi-Omics Foundation Model] Han et al.로 scFM benchmark — 1.5M 세포 real-world 임상/전임상 데이터 + scGPT_CP fine-tuning 최고 + scVI 전체 1위 + Pareto Front-1 hit(bioRxiv 2026) + Pedrocchi et al.로 SAEs로 scGPT·scFoundation·Geneformer 내부 메커니즘 해석 + batch-associated features 억제로 technical variation↓ + drug-encoding features 활성화로 drug-perturbed states 유도 확인(bioRxiv 2026) + Yan et al.로 scFM learnability 평가 — perturbation prediction limited gains + bigger model ≠ better performance 확인(BMC Genomics 2026): foundation model Accelerating(가속) 동시 확인** Single-Cell Foundation Model의 **real-world benchmark 한계 실증 + interpretability breakthrough + learnability evaluation(Accelerating)**이 출처에서 동시에 확인된다[9][10][11]. **scFM Real-World Benchmark: 1.5M 세포 + scVI 전체 1위[9]** Siyu Han et al.(bioRxiv 2026)의 연구는 scFM benchmark를 수행한다[9]. 1.5M 세포 이상의 임상/전임상 데이터에서 scGPT, scGPT_CP, scFoundation, scMulan, CellFM을 평가했다. **Fine-tuning이 technical correction 성능 향상**시켰으며 foundation models 중 **scGPT_CP가 가장 좋은 성능**. 그러나 전체적으로 **scVI baseline이 multi-metric Leximax ranking으로 1위**를 차지하고 Pareto Front-1 hit을 달성했다. 핵심: scFM real-world benchmark에서 baseline 우위 재확인 — 가속화. **SAEs로 scFM Interpretability Breakthrough[10]** Flavia Pedrocchi et al.(bioRxiv 2026)의 연구는 sparse autoencoders로 scFM 내부 구조를 분석한다[10]. scGPT, scFoundation, Geneformer 3개 scFM 분석 결과: **diverse and complex biological + technical signals**이 hidden states에서 발견 — pretrained model에서 이미 emergence. ** SAE-derived features의 행동 연결**: batch-associated features 억제 → unwanted technical variation↓ + biological signal 보존; drug-encoding features 활성화 → drug-perturbed states로 유도(농도 의존적). **통제 가능성**: 해석 가능한 + 통제 가능한 scFM 개발 경로 제시. 핵심: SAEs로 scFM interpretability breakthrough — 통제 가능성 가속화. **scFM Learnability: Bigger ≠ Better[11]** Yuhai Yan et al.(BMC Genomics 2026)의 연구는 scFM learnability를 평가한다[11]. Geneformer와 scGPT를 perturbation prediction과 cell type annotation tasks에서 평가한 결과: **cell type annotation에서는 대규모 pretrained의 이점** 있으나, **perturbation prediction에서는 limited gains**. **Model size 증가가 성능 보장하지 않음** — bigger model ≠ better performance. 단순한 statistics以上的을キャプチャ하지 않을 가능성. **향후 방향**: task-specific architectures + biology-informed priors 필요. 핵심: scFM learnability evaluation — bigger ≠ better 인식 가속화. **10월 3일 Converging(Wang SCMBench + Ji CAPTAIN + Cen review) vs 오늘의 차별점**: 10/03이 **Wang Nature Communications SCMBench**으로 FM vs DM 성능 격차를, **Ji CAPTAIN**으로 382 proteins multimodal을, **Cen MedComm**으로 comprehensive review를 제시했다면, 오늘은 **Han bioRxiv**으로 **1.5M 세포 real-world benchmark에서 scVI 전체 1위**를(실제 적용 한계 가속화), **Pedrocchi bioRxiv**으로 **SAEs로 scFM interpretability breakthrough + 통제 가능성**을(해석 가능성 가속화), **Yan BMC Genomics**으로 **bigger model ≠ better performance**를(학습 효율성 한계 가속화) 동시에 제시한다. Converging(10/03) → 한계 실증 + 해석 breakthrough + 학습 효율성 인식 가속화 Accelerating(10/04). 실무 함의: 단일세포 연구팀에서 Pedrocchi et al.의 SAE approach를 scFM 통제 전략에 적용해야 한다. *출처: [Han scFM Real-World Benchmark bioRxiv 2026](https://consensus.app/papers/details/3e7944ef6ab85bb99aaeb74de2c3dca4/), [Pedrocchi SAE scFM Interpretability bioRxiv 2026](https://consensus.app/papers/details/e6cfd3c27d8457d8bff72f9aac814b588/), [Yan scFM Learnability BMC Genomics 2026](https://consensus.app/papers/details/db23619e10075c0eb0957368f25ba7de/)* *#SingleCell #FoundationModel #Han #scFM #RealWorld #bioRxiv #15MillionCells #scVI #scGPT_CP #FineTuning #ParetoFront #Pedrocchi #SAE #SparseAutoencoder #Interpretability #BatchEffect #DrugEncoding #Yan #scFM #Learnability #BiggerNotBetter #PerturbationPrediction #CellTypeAnnotation #AcceleratingDay #RealWorldLimitation #InterpretabilityBreakthrough #LearnabilityLimit #BiomedicalAI #DailyReport* --- ### Post 6: FDA/규제 — Kresladi March 2026 Approval + Platform-Aligned AI/ML Convergence: Accelerating 📋 **[FDA/규제] Sheikh et al.로 Kresladi FDA 2026년 3월 26일 승인 — LAD-I gene therapy + ITGB2 hematopoietic stem cell editing + 구체적 approval 현실(Annals of Medicine 2026) + Oo et al.로 FDA platform-aligned risk-based + plausible mechanism + CMC flexibility + AI/ML analytics dose selection·safety evaluation·durability prediction convergence(J Clinical Pharmacology 2026) + Shahzad et al.로 FDA CGT 38개 승인 assessment — 86.8% orphan + 92.1% expedited + 73.7% single study + 73.4% PMR/PMC(Clinical Pharmacology Therapeutics 2026): FDA/규제 Accelerating(가속) 동시 확인** FDA 규제 영역의 **2026년 구체적 제품 승인 + 플랫폼 규제 AI/ML convergence(Accelerating)**이 출처에서 동시에 확인된다[12][13][14]. **Kresladi FDA Approval March 2026: LAD-I Gene Therapy[12]** M. Sheikh et al.(Annals of Medicine and Surgery 2026)의 연구는 Kresladi FDA 승인을 분석한다[12]. **Leukocyte Adhesion Deficiency-I(LAD-I)** 치료를 위한 유전자 치료제로, **2026년 3월 26일 FDA 승인**을 받았다. **ITGB2 유전자 편집**으로 환자 자신의 조혈줄기세포를 유전자 편집하여 ITGB2 발현을 회복한다. **HLA 일치 형제 기증자 없는 LAD-I 소아 환자 치료용**으로 승인되었다. 핵심: Kresladi FDA March 2026 승인 — 구체적 제품 승인 가속화. **FDA Platform-Aligned AI/ML Analytics Convergence[13]** C. Oo et al.(J Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals의 evolvolution과 regulatory framework를 분석한다[13]. FDA의 **platform-aligned, risk-based initiatives**: plausible mechanism framework, CMC flexibility initiative, advanced manufacturing technologies program. **AI/ML-enabled analytics**가 dose selection, safety evaluation, durability prediction에서 적용 확대. individualized, mechanistically targeted, potentially curative products 지원을 위한 regulatory framework의 발전을 분석한다. 핵심: FDA platform-aligned + AI/ML analytics convergence — 규제-기술 통합 가속화. **FDA CGT 38개 Approval Assessment: 86.8% Orphan + 92.1% Expedited[14]** Mahnum Shahzad et al.(Clinical Pharmacology & Therapeutics 2026)의 연구는 FDA CGT 38개 승인의 evidence profile을 분석한다[14]. **86.8% orphan designation**, **92.1% expedited pathway**, **73.7% single pivotal study**, **44.7% surrogate endpoints exclusively**, **73.4% PMR/PMC**. 17.9%만 primary clinical efficacy endpoint 포함. Timely access 우선과 limited premarket data 의존의 tradeoff를 지적한다. 핵심: FDA CGT approval assessment 구체적 수치 — 규제 평가 가속화. **10월 3일 Converging(Sheikh Kresladi March 2026 + Oo platform + Shahzad approval) vs 오늘의 차별점**: 10/03이 **Sheikh Annals**으로 Kresladi March 2026 승인을, **Oo J Clinical Pharmacology**으로 platform-aligned를, **Shahzad Clinical Pharmacology**으로 approval assessment 수치를 제시했다면, 오늘은 **Sheikh 재확인**으로 **LAD-I gene therapy + ITGB2 hematopoietic stem cell editing**이라는 구체적 치료 메커니즘을(제품 승인 가속화), **Oo 재확인**으로 **AI/ML analytics dose selection·safety·durability convergence**를(규제-기술 통합 가속화), **Shahzad 재확인**으로 **86.8% orphan + 92.1% expedited + 73.7% single study** 구체적 수치를(규제 평가 가속화) 동시에 제시한다. Converging(10/03) → 제품 승인 + 규제-기술 통합 + 규제 평가 가속화 Accelerating(10/04). 실무 함의: Regulatory Affairs팀에서 Sheikh et al.의 Kresladi 구체적 승인 데이터를 gene therapy regulatory strategy에 반영해야 한다. *출처: [Sheikh Kresladi LAD-I FDA Approval Annals of Medicine 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Oo FDA Platform AI Analytics J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Assessment Clinical Pharmacology Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/)* *#FDA #GeneTherapy #Kresladi #LADI #ITGB2 #March2026 #Sheikh #AnnalsOfMedicine #HematopoieticStemCell #GeneEditing #Oo #JClinicalPharmacology #PlatformAligned #AIML #Analytics #DoseSelection #SafetyEvaluation #DurabilityPrediction #Shahzad #ClinicalPharmacology #OrphanDesignation #ExpeditedPathway #SingleStudy #PMR #PMC #AcceleratingDay #ProductApproval #RegulatoryTechConvergence #AssessmentAccelerated #BiomedicalAI #DailyReport* --- ### Post 7: Spatial Transcriptomics — 5-Platform Head-to-Head Benchmark + Pan-Cancer Niche: Accelerating 🗺️ **[Spatial Transcriptomics] Cervilla et al.로 spatial transcriptomics 5개 플랫폼 head-to-head FFPE benchmark — Visium v1/v2/HD + Xenium + CosMx + RNA-protein decoupling + spatial heterogeneity 확인(Genome Biology 2026) + Li et al.로 pan-cancer 56 LCPs + 13 niches + Niche_4(macrophage+tumor) poor prognosis + Niche_11(macrophage+immune) better survival(Cell Reports Medicine 2026) + Zhang et al.로 SCLC CosMx 600K 세포 + PIHs-1 survival predictor + lymph node metastasis(Cell Reports Medicine 2026): spatial transcriptomics Accelerating(가속) 동시 확인** Spatial transcriptomics의 **5개 플랫폼 기술적 convergence + niche survival analysis(Accelerating)**가 출처에서 동시에 확인된다[15][16][17]. **5-Platform Head-to-Head Benchmark: Technical Convergence[15]** Sergi Cervilla et al.(Genome Biology 2026)의 연구는 5개 공간 전사체 플랫폼을 동일한 FFPE human tumor sections에서 head-to-head comparison한다[15]. **Visium v1, Visium v2/CytAssist, Visium HD, Xenium, CosMx**를 same samples에서 직접 비교한다. **평가 영역**: transcript·UMI detection, gene-histology concordance, cell type recovery, targeted protein panel integration. **Visium targeted protein data + matched RNA profiles 통합**: RNA-protein decoupling + spatial heterogeneity 확인. **Xenium Multi-Tissue(377 genes) vs Xenium Prime(5,000 genes) same-sample comparison**: transcript recovery와 spatial signal의 주요 차이 확인. 핵심: 5개 플랫폼 head-to-head benchmark — 기술적 convergence 가속화. **Pan-Cancer 56 LCPs + Niche Survival Analysis[16]** Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 12개 암종 373개 검체에서 56개 지역 세포 프로그램(LCPs)과 13개 반복 niches를 분석한다[16]. **Niche_4(macrophage + tumor cell)**: poor prognosis + immunotherapy resistance 연관. **Niche_11(macrophage + immune cell)**: better survival + treatment response 연관. **Ligand-receptor analysis**: niche-shared와 niche-specific interactions 확인. 핵심: pan-cancer niche survival analysis — 생물학적 convergence 가속화. **SCLC 600K Cells + PIHs-1 Survival Predictor[17]** Zicheng Zhang et al.(Cell Reports Medicine 2026)의 연구는 CosMx Spatial Molecular Imager로 SCLC의 공간적 세포 생태계를 75명 환자 105개 검체에서 600,000개 이상의 세포를 profiling한다[17]. **3개 LNM-enriched malignant subclusters**: distinct metabolic과 angiogenic programs. **Vascular-immune crosstalk**: endothelial cells가 cytotoxic T cells와 perivascular niche 형성. **Pan-immune hotspot(PIHs-1)**: 독립적 survival predictor. 핵심: SCLC 600K spatial map + PIHs-1 survival predictor — 임상적용 가속화. **10월 3일 Converging(Cervilla 5-platform + Li 56 LCPs + Wen comprehensive) vs 오늘의 차별점**: 10/03이 **Cervilla Genome Biology**으로 5개 플랫폼 benchmark를, **Li Cell Reports Medicine**으로 56 LCPs + Niche_4/Niche_11을, **Wen Cell Death Discovery**으로 comprehensive review를 제시했다면, 오늘은 **Cervilla 재확인**으로 **RNA-protein decoupling + spatial heterogeneity 구체적 메커니즘**을(기술 convergence 가속화), **Li 재확인**으로 **Niche_4 poor prognosis + Niche_11 better survival의 구체적 생존 예측력**을(생물학적 convergence 가속화), **Zhang 재확인**으로 **PIHs-1 survival predictor의 독립적 예측력**을(임상적용 가속화) 동시에 제시한다. Converging(10/03) → 기술 convergence + 생물학적 convergence + 임상적용 가속화 Accelerating(10/04). 실무 함의: 면역종양학팀에서 Li et al.의 Niche_4/Niche_11 결과를 immunotherapy patient selection에 적용해야 한다. *출처: [Cervilla 5-Platform Benchmark Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/), [Li Pan-Cancer Spatial Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Zhang CosMx SCLC Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)* *#SpatialTranscriptomics #Cervilla #GenomeBiology #Benchmark #5Platforms #Visium #Xenium #CosMx #FFPE #RNADecoupling #SpatialHeterogeneity #Li #PanCancer #56LCPs #Niche4 #Niche11 #Macrophage #Tumor #Prognosis #ImmunotherapyResistance #Zhang #CosMx #SCLC #600KCells #PIHs1 #SurvivalPredictor #LymphNodeMetastasis #AcceleratingDay #TechnicalConvergence #BiologicalConvergence #ClinicalApplication #BiomedicalAI #DailyReport* --- ### Post 8: 오늘의 요약 — Accelerating(가속) Day 핵심 정리 🧬 **오늘 6개 영역 핵심 요약:** 10/04(Accelerating)의 핵심: Converging(10/03)된 기술들이 **실질적 임상·규제 성과로 가속화(Accelerating)하는 날**이었다. **1. PE First-in-Human Functional Restoration(Lushington Molecular Therapy 2026)**: PE first-in-human study에서 functional restoration + promising safety profile 확인 — 임상 가속화里程碑[1]. **2. PE7 Evolution + In Vivo Delivery Breakthrough(Jong BMB Reports 2026)**: PE1→PE7까지 7단계 evolution + nanoparticles/split viral systems breakthrough — 기술 evolution 가속화[2]. **3. AI-Designed TNIK Phase IIa Efficacy(Yoo BJC Reports 2026)**: AI-designed TNIK inhibitor Phase IIa efficacy + adaptive trial design + federated model validation — AI drug discovery 임상 milestone 가속화[4]. **4. 2026 Pharma AI Deal Flurry(Lin GEN Biotechnology 2026)**: Isomorphic Labs·Exscientia·Recursion Pharologi 대규모 투자 급증 — pharma AI investment accelerated[5]. **5. AlphaFold Drug Discovery Limitation(Singh Current Opinion Structural Biology 2026)**: Protein-Ligand data 필요성 + hierarchical framework로 tasks 분류 + frontier model dataset 필요성 — 한계 인식 가속화[6]. **6. SAEs로 scFM Interpretability Breakthrough(Pedrocchi bioRxiv 2026)**: batch-associated features 억제 + drug-encoding features 활성화로 drug-perturbed states 유도 — 해석 가능성 breakthrough[10]. **7. Kresladi FDA March 2026 Approval(Sheikh Annals of Medicine 2026)**: LAD-I gene therapy + ITGB2 hematopoietic stem cell editing 2026년 3월 26일 승인 — 구체적 제품 승인 가속화[12]. **8. 5-Platform Head-to-Head Benchmark(Cervilla Genome Biology 2026)**: Visium HD·Xenium·CosMx 등 5개 플랫폼 same-sample comparison + RNA-protein decoupling 확인 — 기술 convergence 가속화[15]. **10월 5일 전망**: Accelerating된 기술들의 임상·규제 성과 가속화가 핵심 변수. 특히 PE first-in-human의 후속 추적 결과, Kresladi LAD-I 치료 전달 구체적 성적, Singh의 frontier model dataset 생성 initiatives가 관전이다. *출처: [Lushington PE First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Jong PE Evolution BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/), [Yu PE Efficiency Advanced Science 2026](https://consensus.app/papers/details/475fc3cbbe805f5e915626f08d2da039/), [Yoo TNIK Phase IIa BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Lin Pharma AI 2026 Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Singh AlphaFold Drug Discovery Limitation Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Chakraborty AlphaFold3 Frontiers AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [Zhang AlphaFold Peptide Biotechnology Advances 2026](https://consensus.app/papers/details/948caefacacc54fcb7706db4d8660a93/), [Han scFM Real-World Benchmark bioRxiv 2026](https://consensus.app/papers/details/3e7944ef6ab85bb99aaeb74de2c3dca4/), [Pedrocchi SAE Interpretability bioRxiv 2026](https://consensus.app/papers/details/e6cfd3c27d8457d8bff72f9aac814b588/), [Yan scFM Learnability BMC Genomics 2026](https://consensus.app/papers/details/db23619e10075c0eb0957368f25ba7de/), [Sheikh Kresladi LAD-I Annals of Medicine 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Oo FDA Platform AI Analytics J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/), [Cervilla 5-Platform Benchmark Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/), [Li Pan-Cancer Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Zhang CosMx SCLC Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)* *#AcceleratingDay #Summary #Lushington #PrimeEditing #FirstInHuman #Jong #PE7 #Evolution #Yu #PEEfficiency #Yoo #TNIK #PhaseIIa #AdaptiveTrial #FederatedModel #Lin #PharmaAI #2026Deals #Singh #AlphaFold #Limitation #ProteinLigand #Chakraborty #AlphaFold3 #Zhang #Peptide #MolecularDynamics #Han #scFM #RealWorld #Pedrocchi #SAE #Interpretability #Yan #Learnability #BiggerNotBetter #Sheikh #Kresladi #LADI #ITGB2 #March2026 #Oo #PlatformAligned #AI #ML #Shahzad #Orphan #Expedited #Cervilla #5Platforms #Benchmark #Li #56LCPs #Niche4 #Niche11 #Zhang #PIHs1 #Accelerating #ClinicalAcceleration #RegulatoryApproval #BiomedicalAI #DailyReport* --- ## Sources [1] [Lushington et al. — A primer on prime: A prime editing update from advances to first-in-human trial. Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/) [2] [Jong et al. — Prime editing updates: technological evolution, methodological expansion, and delivery strategies for in vivo applications. BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/) [3] [Yu et al. — Evolution of Prime Editing: Enhancing Efficiency and Expanding Capacity. Advanced Science 2026](https://consensus.app/papers/details/475fc3cbbe805f5e915626f08d2da039/) [4] [Yoo et al. — Precision oncology in the age of AI: lessons from AI-driven drug discovery and clinical translation. BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/) [5] [Lin — Pharma Bets Big on AI Platforms with Flurry of 2026 Deals. GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/) [6] [Singh et al. — More Protein-Ligand data is needed for AlphaFold-like Models to enable drug discovery. Current Opinion in Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/) [7] [Chakraborty, Bhattacharya & Lee — The transformative impact of AI-enabled AlphaFold 3: evolution, current status, and future prospects. Frontiers in AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/) [8] [Zhang et al. — AlphaFold-based peptide structure prediction: Opportunities, limitations, and future directions. Biotechnology Advances 2026](https://consensus.app/papers/details/948caefacacc54fcb7706db4d8660a93/) [9] [Han et al. — Benchmarking single-cell foundation models for real-world RNA-seq data integration. bioRxiv 2026](https://consensus.app/papers/details/3e7944ef6ab85bb99aaeb74de2c3dca4/) [10] [Pedrocchi et al. — Sparse Autoencoders Reveal Interpretable Features in Single-Cell Foundation Models. bioRxiv 2026](https://consensus.app/papers/details/e6cfd3c27d8457d8bff72f9aac814b588/) [11] [Yan et al. — Evaluating the learnability of single-cell large language models on multiple tasks. BMC Genomics 2026](https://consensus.app/papers/details/db23619e10075c0eb0957368f25ba7de/) [12] [Sheikh et al. — Gene therapy for leukocyte adhesion deficiency type I: FDA approval, clinical evidence, and future perspectives. Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/) [13] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/) [14] [Shahzad et al. — Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies. Clinical Pharmacology & Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/) [15] [Cervilla et al. — A technical comparison of spatial transcriptomics platforms across six cancer types. Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/) [16] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/) [17] [Zhang et al. — Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer. Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)
Research Pulse·2026-10-04
Research Pulse — 2026-10-04
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief